论文部分内容阅读
氨丁卡那霉素(Amikacin)是一种由卡那霉素衍化的、半合成抗菌素,体外证明对固紫阴性杆菌具广谱抗菌作用。 18例19～79岁患者发生19次严重固紫阴性杆菌感染,除2例外,均继发于原有的内科或外科疾病。泌尿道感染5次,肺感染4次,软组织感染6次,骨感染2次,胸腔感染3次,胆道感染2次。感染2～30天(平均11.7天)后才用氨丁卡那霉素治疗。所有患者都曾用庆大霉素及局部排液治疗无效(总剂量80毫克～96克)。此外还用过氨苄青霉素、新青霉素Ⅱ、羧苄青霉素、多粘菌素B、磺胺异恶唑、TMP-SMZ、先锋霉素Ⅰ、先锋霉素Ⅵ和氯霉素。15例于治疗前24
Amikacin is a kanamycin-derived, semi-synthetic antibiotic that demonstrates broad-spectrum antibacterial activity against solid-violet-negative bacilli in vitro. Nineteen severe solid-violet-negative bacilli infections occurred in 18 patients 19-79 years of age, with the exception of two who were secondary to the original medical or surgical condition. 5 urinary tract infections, 4 lung infections, 6 soft tissue infections, 2 bone infections, 3 chest infections, and 2 biliary tract infections. Infected with 2 to 30 days (average 11.7 days) with amikacin treatment. All patients have been treated with gentamicin and local drainage invalid (total dose of 80 mg ~ 96 g). In addition, ampicillin, penicillin Ⅱ, carbenicillin, polymyxin B, sulfisoxazole, TMP-SMZ, cephalosporin Ⅰ, cephalosporin Ⅵ and chloramphenicol were also used. 15 cases before treatment 24